1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

BioInvent Stumbles In Busy Multiple Myeloma Space

 
• By Sukaina Virji

The US FDA has halted the biotech company’s Phase II trial in multiple myeloma, a space that has seen a number of new drugs recently enter the market.

BioInvent International AB has been slapped with a full clinical hold by the US FDA for its Phase II study with the antibody BI-505 in patients with multiple myeloma, which is being conducted at Penn Medicine in the US.

The company’s share price dropped by 22% on the news (Nov. 8). With the multiple myeloma space seeing a flurry...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

AstraZeneca Faces Close Race With Mineralys After Phase III Hypertension Readout

 
• By Andrew McConaghie

There is little to divide the Phase III results for the two aldosterone synthase inhibitors, though AstraZeneca’s combination and cardiovascular outcomes studies could bear fruit in the long-term.

BeOne Preps For Sonrotoclax MCL Filing, With Sights Set On AbbVie/Roche’s Territory

 
• By Alaric DeArment

The biotech announced positive topline Phase I/II results for the BCL2 inhibitor in late-line mantle cell lymphoma, with Phase III studies underway in chronic lymphocytic leukemia.

J&J Keeps Faith In Nipocalimab’s $5bn Sales Target Despite RA Trial Setback

 
• By Manas Mishra

Johnson & Johnson will push ahead with its 'pipeline-in-a-product' plans for Imaavy despite pulling the plug on its development in rheumatoid arthritis.